NASDAQ · ARVNHealthcarePharmaceuticals

Arvinas financials

$7.50−0.13%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
FY20
Dec 31
FY19
Dec 31
FY18
Dec 31
Revenue$262.6M$263.4M$78.5M$131.4M$53.6M$25.9M$43.0M$14.3M
Gross profit$262.6M$263.4M$78.5M$131.4M$53.6M$25.9M$43.0M$14.3M
Gross margin100.0%100.0%100.0%100.0%100.0%100.0%100.0%100.0%
Operating income-$118.5M-$250.2M-$401.5M-$263.2M-$188.4M-$120.8M-$51.5M-$43.8M
Net income-$80.8M-$198.9M-$367.3M-$282.5M-$191.0M-$119.3M-$70.3M-$239.8M
Net margin−30.8%−75.5%−467.9%−215.0%−356.3%−460.6%−163.5%−1674.5%
Diluted EPS$-1.14$-2.77$-6.62$-5.31$-3.82$-3.02$-2.13$-25.45
EBITDA-$111.2M-$241.0M-$395.4M-$255.1M-$182.0M-$116.7M-$49.9M-$43.1M
Operating cash flow-$273.8M-$259.3M-$347.8M-$273.5M$559.4M-$89.7M-$40.6M-$16.1M
Free cash flow-$275.7M-$261.1M-$350.7M-$280.3M$554.7M-$96.1M-$46.9M-$18.9M
Diluted shares70.9M71.9M55.5M53.2M50.0M39.5M32.9M9.4M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$142.9M$100.5M$311.7M$81.3M$108.3M$588.4M
Short-term investments$542.5M$938.9M$949.3M$1.12B$1.39B$100.2M
Total debt$400.0K$600.0K$800.0K$1.0M$1.0M$2.0M
Total assets$717.9M$1.09B$1.30B$1.27B$1.58B$717.4M
Total liabilities$284.0M$529.7M$644.6M$703.9M$799.9M$75.2M
Shareholders' equity$433.9M$561.7M$660.0M$564.9M$781.7M$642.2M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology